Jardins: nā ʻōlelo i hoʻohana ʻia ai, nā mea hoʻohālike a me nā loiloi, nā kumukūʻai ma nā lāʻau lapaʻau o Lūkia

Hoʻohana ʻia ka hoʻohana ʻana o ka empagliflozin i ka wā hapai ma muli o ka lawa ʻole o ka ʻikepili i ka pono a me ka palekana.
ʻO nā ʻikepili i loaʻa i nā noi preclinical i nā holoholona e hōʻike i ka komo ʻana o ka empagliflozin i loko o ka waiū umauma. Hōʻalo ʻia ka nui o ka hoʻolaha ʻana i nā pēpē a me nā keiki i ka wā o ka hoʻoulu ʻana. Hoʻohana ʻia ka hoʻohana ʻana o ka empagliflozin i ka wā o ka hoʻoulu ʻana. Inā pono e hoʻohana i ka empagliflozin i ka wā o ka hoʻouluʻana, pono ke hōʻuluʻulu i ka umauma.

ʻLoe a me ke kākele

Hoʻololi a i ʻole hoʻohui hui ʻana
ʻO ka papa hoʻomaka ʻia e 10 mg (1 papa me kahi ala o 10 mg) hoʻokahi i ka lā, ma ka waha.
Inā hāʻawi ʻole ka lāʻau i kēlā me kēia lā iā 10 mg i ka mana glycemic kūpono, hiki ke hoʻonui ʻia i ka make i 25 mg (1 papa me kahi maʻi o 25 mg hoʻokahi i ka lā). ʻO ka dose kiʻekiʻe loa i kēlā me kēia lā he 25 mg.
Hiki ke lawe ʻia ka lāʻau JARDINS e like me ka ʻaina o kēlā me kēia manawa o ka lā.
Nā hana e hoʻōki ai i ka hopu ʻana i hoʻokahi helu o nā lāʻau
Ke hoʻoluhi nei i kahi maʻa, pono e lawe ka mea maʻi i ka lāʻau ma ka manawa e hoʻomanaʻo ai i kēia.
Mai lawe i kahi pāpālua pālua i ka lā hoʻokahi.
Nā hui ahonui kūikawā
In renal gagal me GFR mai 45 a 90 ml / min / 1.73 m2, ʻaʻole pono ka hoʻoponopono ʻana i nā pualikoa.
ʻO nā mea maʻi me ka pani ʻole ʻana me GFR e emi iho ma mua o 45 ml / min / 1.73 m2 ʻaʻole i ʻōlelo ʻia e hoʻohana i ka lāʻau lapaʻau ma muli o ka pono ʻole.
ʻO nā mea maʻi me ka maʻi luhi functioning lawelawe ʻole ʻaʻole pono.

Ke keu

Nā Hoʻomaka
I ka wā o ka hoʻokolohua ʻana i nā maʻi lapaʻau, ʻoi aku ka nui o nā empagliflozin i hōʻea i 800 mg (32 mau manawa nui loa i kēlā me kēia lā) i nā mea hoʻoikaika olakino a me nā helu he nui i hōʻea i ka 100 mg (4 mau manawa nui loa i kēlā me kēia lā) i nā mea maʻi me ka maʻi diabetes type 2 ʻO ka piʻi ʻana i loko o ka urine volume ʻaʻole i hilinaʻi i ka nui o ka make a ʻaʻohe hanana koʻikoʻi no ka maʻi. ʻAʻoheʻike i kahi hāmeʻa ma mua o 800 mg.
Hoʻomaʻamaʻa
I kahi hihia o ka overdose, ua hōʻike ʻia e kāʻili ʻia ka lāʻau kū ʻole mai ka gastrointestinal tract, ka mālama paʻa ʻana a me ka mālama maʻi.

Hoʻopili pū me nā lāʻau ʻē aʻe
I ka hōʻike vitro hoʻonaninau lāʻau
ʻAʻole i hoʻopaʻa ai ʻo Empagliflozin i ka hana, ʻaʻole hoʻohālikelike, a i ʻole hoʻohiolo iā CYP450 isoenzymes. ʻO ke ala nui o ka metabolism human empagliflozin ka glucuronidation me ka komo ʻana o ka uridine-5′-diphospho-glucuronosyltransferases UGT2B7, UGT1A3, UGT1A8 a me UGT1A9. ʻAʻole ʻo Empagliflozin e kāohi iā UGT1A1. ʻO nā hōʻiliʻili o ka lālani o ka empagliflozin a me nā lālani i hoʻohālikelike i ka CYP450 a me UGT1A1 isoenzymes i manaʻo ʻia i like ʻole.
ʻO Empagliflozin kahi papa hana no ka glycoprotein P (P-gp) a me nā ʻōnaehana pale o ka pale umauma (BCRP). akā, ʻaʻole i pale ʻia nā dosis therapeutic i kēia mau protein. Ma muli o ka ʻikepili mai nā haʻawina vitro, ʻike ʻia ka hiki ʻole o ka empagliflozin ke hoʻopili me ka lāʻau lapaʻau e substrate no ka glycoprotein P (P-gp) i ka hiki ʻole. ʻO Empagliflozin kahi papa lepo no nā mea lawe anionic organik: OATZ, OATP1B1 a me OATP1VZ, akā ʻaʻole ia kahi papa kuhikuhi no ka mea lawe anionic meaola 1 (OAT1) a me nā mea lawe cationic carriers 2 (OST2). Eia naʻe, ʻo ka hoʻopili ʻana i nā lāʻau lapaʻau ka empagliflozin me nā lāʻau lapaʻau nā substrate no nā mea lawe palaka e pili ana i luna e manaʻo ʻia he hana ʻole ʻole.
Ma ka vivo lāʻau e hoʻoponopono nei i ka loiloi
ʻAʻole loli i ka pharmacokinetics o empagliflozin i nā mea hana olakino maikaʻi i ka wā i hoʻohana pū ʻia me metformin, glimepiride, pioglitazone, sitagliptin, linagliptin, warfarin, verapamil, ramipril, simvastatin, torasemide a me hydrochlorothiazide. ʻO ka hui pū ʻana o ka empagliflozin me gemfibrozil, rifampicin a me ka probenecid i hōʻike i ka hoʻonui ʻia ʻana o ka AUC o empagliflozin e 59%, 35% a me 53%, akā, ʻaʻole i manaʻo ʻia kēia mau loli.
ʻAʻohe o ka maʻi nui o Empagliflozin e pili i ka pharmacokinetics o ka metformin, glimepiride, pioglitazone, sitagliptin, linagliptin, warfarin. digoxin, ramipril, simvastatin, hydrochlorothiazide, torasemide a me nā mea hoʻohālikelike waha.
Diuretics
Hiki i ka Empagliflozin hiki ke hoʻonui i ka hopena diuretic o thiazide a me ka "loop" diuretics, a ma ia manawa e hoʻonui ai i nā kīʻaha o ka dehydration a me ka hypotension arterial.
ʻO ka insulin a me nā lāʻau lapaʻau e hoʻoikaika i kāna hūnā
ʻO ka insulin a me nā lāʻau lapaʻau e hoʻoikaika i kāna mea huna, e like me ka sulfonylureas, e hoʻonui i ka ʻeha o ka hypoglycemia. No laila, me ka hoʻohana pū ʻana o empagliflozin me ka insulin a me nā lāʻau lapaʻau e hoʻoikaika ai i kona ʻimi, pono paha e hōʻemi i kā lākou dosis, i mea e pale ai i ka maʻi o ka hypoglycemia.

Nā ʻōlelo kikoʻī

ʻAʻole ʻōlelo ʻia ka lāʻau JARDINS no nā mea maʻi me ka maʻi mellitus type 1 me ka mālama ʻana i ka ketoacidosis maʻi.
ʻO ka nui loa o nā lā o JARDINS e loaʻa ai ka 113 mg o ka lactose, no laila ʻaʻole pono e hoʻohana ʻia ka lāʻau i nā mea maʻi me nā maʻi i hoʻoili ʻia e like me ka lactase defolate, ka lactose intolerance, glucose-galactose malabsorption.
Ua hōʻike ʻia nā haʻawina haukaʻa ʻo ka mālama ʻana me ka empagliflozin ʻaʻole i alakaʻi i kahi hoʻonui o ka puʻuwai cardiovascular. ʻO ka hoʻohana ʻana o ka empagliflozin i kahi lāʻau o 25 mg ʻaʻole i alakaʻi i ka lōʻihi o ka manawa QT.
Me ka hoʻohana pū ʻana o ka lāʻau JARDINS me nā derebatives sulfonylurea a i ʻole me ka insulin, he ʻaina e hoʻemi ʻia ana i ka hopena o ka sulfonylurea / insulin derivatives ma muli o ka loaʻa o ka maʻi hypoglycemia.
ʻAʻole i aʻo ʻia i nā hoʻohui o nā lāʻau lapaʻaka hypoglycemic
ʻAʻole i aʻo ʻia ʻo Empagliflozin i ka hoʻohui pū ʻana me ka pomo ponaide 1 like me glucagon-like (GLP-1).
ʻO ka nānā ʻana me ka nānā ʻana i nā pēpē
ʻO ka hana o ka lāʻau JARDINS hilinaʻi i ka hana o nā keiki. No laila, paipai ʻia e nānā i nā hana o ka renal ma mua o kona koho ʻana a me ka manawa maʻamau i ka wā o ka mālama ʻana (ma ka liʻiliʻi hoʻokahi hoʻokahi manawa), a ma mua o ke koho ʻana i ka maʻi concomitant, ka mea hiki ke hoʻopilikia i ka hana o ka maʻi. ʻO nā mea maʻi me ka pani ole ʻana (GFR ma mua o 45 mlmin). lawe ʻole ʻia ka lāʻau.
ʻO nā maʻi maʻi
ʻO nā maʻi i hala ka makahiki 75 a ʻoi aku paha e hoʻonui i ka nui o ka puʻuwai. I kēlā mau mea maʻi i mālama ʻia me ka empagliflozin, ʻoi aku ka maikaʻi loa o nā hopena i loaʻa e ka hypovolemia (hoʻohālikelike ʻia me nā mea maʻi e loaʻa ana i ka placebo). Loaʻa ka ʻike me ka empagliflozin i nā mea maʻi ma luna o ka 85 mau makahiki o ka makahiki, no laila, ʻaʻole i kuhikuhi ʻia e kuhikuhi i ka lāʻau lapaʻau JARDINS i nā poʻe maʻi i ʻoi aku ma mua o ka 85 mau makahiki.
Hoʻohana i ka mea maʻi ma ka hopena o ka uluʻana o ka hypovolemia
Wahi a ka hana o ka hana, ʻo ka alakaʻi o ka lāʻau JARDINS hiki ke alakaʻi i ka hoʻemi iki ʻana i ke kahe o ke koko. No laila, pono e hoʻohana ʻia ka lāʻau lapaʻau me ka mālama ʻana i nā hihia kahi i kapa ʻole ʻia ai ke kaomi koko, ʻaʻole pono, no ka laʻana, i nā mea maʻi me nā maʻi cardiovascular, nā poʻe maʻi e lawe nei i nā lāʻau antihypertensive (me ka mōʻaukala o ka hypotension arterial), a me nā mea maʻi ma mua o 75 mau makahiki.
Ma ka hanana e lawe ana ka mea maʻi i ka lāʻau JARDINS. nā kūlana e hiki ke alakaʻi i ka neʻe ʻana i ka wai (me ka laʻana, me nā maʻi o ka ʻalā o ka gastrointestinal), ke ʻano o ka mea maʻi, ka mālama ʻia ʻana o ke koko me ka mālama pono ʻana, me ka hematocrit a me ka kaulike electrolyte. Hiki ke koi i kahi manawa pōkole, e hoʻihoʻi i ka kaulike wai, hoʻopau i ka lāʻau.
ʻAʻohe maʻi ʻeha
ʻO ka ulu ʻana o nā hopena like e like me ka maʻi urinary tract i hoʻohālikelike ʻia me ka empagliflozin ma ke ʻano o 25 mg a me ka placebo, a ʻoi aku ke kiʻekiʻe a me ka empagliflozin ma kahi pākē o 10 mg. ʻO nā maʻi ʻeha o ka urinary (e like me ka pyelonephritis a me ka urosepsis) i nānā me ka like o ka like me nā mea maʻi e lawe ana i ka empagliflozin a me ka placebo. I ka hihia o nā maʻi o ka urinary tract, pono kahi hoʻopau kīnā ʻole o ka maʻi emagliflozin.
ʻĀina Hana Urinalysis
Wahi a ka hana o ka hana i nā poʻe maʻi e lawe nei i ka lāʻau JARDINS, hoʻoholo ka glucose i ka pāʻai.

Hoʻopilikia i ka hiki ke hoʻokau i nā kaʻa a me nā māka
Ua mālama ʻia nā haʻawina hauoli e pili ana i ka hopena o ka empagliflozin e hiki ai ke hoʻokele i nā kaʻa a ʻaʻole i lawe ʻia nā hana. E mālama pono i ka poʻe maʻi i ka wā e kaʻi aku ana i nā kaʻa a me nā hana, ʻoiai ke hoʻohana ʻana i ka lāʻau JARDINS (ʻoi aku ka hoʻohui me ka sulfonylurea derivatives a / a i ʻole insulin), ulu ka hypoglycemia.

Loaʻa i nā mele Jardins Substitutes

NovoNorm (nā papa) Kauka: 163

ʻOi aku ka maʻalahi o ka analogue mai ka 59 mau rubles.

ʻO NovoNorm kahi papa papaʻaina mai nā hui like ʻole, akā me nā ʻano hana like ʻole. Hoʻohana ʻia ka Repaglinide ma aneʻi ma kahi helu o ka 0.5 a hiki i ka 2 mg. Hoʻohālikelike nā ʻōkuhi no ke kuhikuhi ʻana, akā ʻokoʻa nā contraindications ma muli o nā DV i nā papa, no laila e heluhelu pono i nā ʻōkuhi a nīnau aku i kāu kauka.

Diagninide (nā papa) Rating: 142

ʻO Diagninide kahi mea hoʻololi i ka Lūkini no ka māhele kumukūʻai like me ka nui o nā papa āpau i kēlā me kēia pā. He ʻokoʻa ka māhele a me nā ʻano o ka mea hana no ka Jardins, akā ua ʻōlelo ʻia no ka mālama ʻana o ka maʻi type 2 me ka maikaʻi o ke kino a me ka meaʻai.

ʻO ka ʻike nui e pili ana i ka lāʻau lapaʻau, kona ʻano

Hoʻohana ʻia ka lāʻau lapaʻau Jardins e kaohi koko i ke wā o ka monotherapy. Eia kekahi, hiki ke hoʻohana ʻia kēia mea hana i ka māhele i ka wā o ka mālama ʻana i ka maʻi maʻi.

Hiki i ka paahana ke hoʻohui pū me kekahi mau lāʻau lapaʻau hypoglycemic ʻē aʻe. Hiki i kēia mau lāʻau lapaʻau ke hoʻohui ʻia i ka insulin a i ʻole ke metformin.

Ke kūʻai aku nei ka lāʻau lapaʻau ma ka mākeke o nā huahana pharmacological i ʻelua mau hopena i ʻokoʻa i ka nui o ka pūnao me ka nui o ka pūnao pākuʻi.

Aia ma muli o ka hāhā o ka pūhui koʻikoʻi nui, aia paha i kahi papa o ka hoʻomākaukau he 10 a 30 mg paha o ka mea hoʻoneʻe.

Ma kahi o ka pūhui koʻikoʻi koʻikoʻi, aia nā huaʻōlelo i loko o kahi papa o ka lāʻau lapaʻau.

• laktosa lactose,
• mikuleka
• Hoʻopiʻi
• sodium polio
• silika
• paʻahau magnesium.

Hoʻopili ʻia nā papa o ka lāʻau lapaʻau, aia nā mea e ʻike nei:

1. Opadra melema,
2. hohaihono,
3. titanium hone
4. ka leʻaleʻa talcum
5. Macrogol 400,
6. melemele ka hao kalona.

Ke hoʻohana nei i kēia lāʻau lapaʻau, pono e hoʻomanaʻo maikaʻi ka hoʻohana ʻana o Jardins e hoʻomaʻamaʻa i ke ʻano o ke kō i loko o ke koko o ka mea maʻi me ka maʻi type kīnā ʻole hiki ʻole ke hoʻopakele i kahi kanaka mai kēia maʻi ʻole.

ʻO nā waiwai nui o ka pharmacological o ka lāʻau

Hoʻohana pinepine ʻia ka lāʻau Jardins i ka lāʻau lapaʻau i kēia manawa e hoʻoponopono i ke kō o ke koko kiʻekiʻe i loko o kahi kanaka me ka maʻi diabetes 2 mau.

ʻO nā loiloi o nā loea lapaʻau e hōʻike ana i kēia mea hana i hiki ke hoʻomohala pono i ka ʻona o ke kō i loko o ke kanaka maʻi a loaʻa i nā hopena maikaʻi loa.

ʻO Empagliflozin, ʻo ia ke kumu hana nui o ka lāʻau lapaʻau, he koho paʻa, hoʻihoʻi hou i ka mea hoʻokūkū ikaika paʻa o ka transporter glucose-hilinaʻi kūikawā.

Mālama kēia pūlea i ka hiki ke hiki ke mālama i ka nui o ke kō i loko o ke kino o ka mea maʻi i loaʻa i ka maʻi diabetes type 2. ʻO ka hopena o ka pahuhopu ikaika o ka lāʻau lapaʻau e kōkua i ka hoʻemi ʻana i ka pae o ka reabsorption glucose i loko o nā hana o ka mōʻī. Ke hoʻohana nei i ka lāʻau lapaʻau, hoʻonui ka nui o ke kō i loko o ka urine, e hāʻawi ana i ka wikiwiki o ka hoʻohemo ʻana o ka nui o ka glucose mai ke kino.

ʻAʻole hoʻopilikia ka hoʻohana ʻana i ka lāʻau i ka hana o nā cell beta. ʻO ka pūnao koʻikoʻi he hopena maikaʻi i ka kiko o ka pancreatic, i mea e kōkua ai e hoʻomaikaʻi i kāna hana ʻana.

ʻO ka hoʻokomo ʻana o ka empagliflozin i loko o ke kino e hoʻopilikia i ke kaʻina o ka puhi ʻana i ka momona a kōkua i ka hoʻemi ʻana i ke kaumaha o ka mea maʻi me ka maʻi diabetes type 2. ʻO kēia hopena hou mai ka hoʻohana ʻana i ka lāʻau lapaʻau ka mea nui no ka poʻe ka nui o ke kau ʻana me ke ʻano maʻi type 2.

ʻO ka hapalua-ola o ka mea hana o ka lāʻau lapaʻau e lawe ʻia ana no 12 mau hola. Ka paʻa mau ʻia i loko o ke kino o ka waiwai ikaika me kahi pākahi hoʻokahi o ka lāʻau i ka lā e loaʻa ana ma hope o ka lawe ʻana i ka hapa ʻelima o ka lāʻau.

Mai ke kino kanaka, a hiki i 96% o ka lāʻau i lawe ʻia ma ka excreted. Hoʻopau ʻia ka hoʻomaʻamaʻa ʻana o nā metabolites me ka hoʻohana ʻana i nā ʻōpū a me nā puʻuwai. Ma o ka ʻōpū, hoʻoneʻe ʻia ke ʻano ikaika. Ke hoʻihoʻi ʻia nei ma o nā ʻōpū, ʻo 50% wale nō o ka hana ikaika o ka lāʻau lapaʻau a i hoʻololi ʻia.

Nui ka manaʻo o ka neʻe ʻana o ka mea hana ikaika ma ke kino i ka loaʻa ʻana i ka mea maʻi o ka renal impaired a i ʻole hepatic function.

ʻO ka paona kino o ke kanaka, ka wahine a me nā makahiki ʻaʻole i hoʻopilikia nui loa i ka pharmacokinetics o ka mea ikaika o ka lāʻau.

Nā ʻōkuhi no ka hoʻohana ʻana i ka lāʻau lapaʻau

Hoʻohana ʻia ka lāʻau no ka mono - a i ʻole ka hōʻola paʻakikī. ʻO ka paona i ʻōlelo ʻia he 10 mg - hoʻokahi papa i kēlā me kēia lā. Hoʻohana ʻia ka lāʻau.

Inā hiki ole i kahi lā o kēlā me kēia lā he 10 mg hiki ke hāʻawi i kahi hopena glycemic maʻamau, hiki ke hoʻonui ʻia ka nui i hoʻohana ʻia i 25 mg i kēlā me kēia lā. ʻO ka palena ʻokoʻa loa o ka lāʻau lapaʻau ke hiki i ka 25 mg.

ʻAe ʻia ka lāʻau lapaʻau e lawe ʻia i kēlā me kēia manawa, me ka ʻano o ka hoʻoponopono ʻaina.

Inā poina ʻoe i ka manawa o ka lawe ʻana i ka lāʻau lapaʻau, ʻaʻole ʻoe e lawe i ʻelua pālua o ka lāʻau i ka lā.

Me kahi kiʻekiʻe o ka hikiʻole o ka renal, ʻaʻole i kuhikuhi ʻia ka lāʻau lapaʻau, ma muli o ka nele o ka pono o ka hoʻohana i ka lāʻau.

Inā loaʻaʻole ka mea maʻi i ka palupalu, i hōʻike ʻia e like me ka palalopona o ke akea, ʻaʻole pono nā koi o ka hoʻoponopono ʻana i ka lāʻau i lawe ʻia.

ʻAʻole ia e hāʻawi i ka lāʻau lapaʻau i ka wā e lawe ai i kahi keiki a me ka umauma, ma muli o ka hapa o ka ʻikepili i ka hopena a me ka palekana o ka lāʻau lapaʻau no ka makuahine a me ke keiki i kēia manawa.

I ka hihia o ka renal gagal, ʻo ka hopena o ka lāʻau lapaʻau e hilinaʻi ana i ke kiʻekiʻe o ka hana ʻole ʻole.

Ke hōʻike ʻia nei e nānā i ka hana o ka maʻi ma mua o ka lāʻau lapaʻau me ka lāʻau lapaʻau, a pono ʻia e nānā i ka hana o ka maʻi i ka liʻiliʻi i hoʻokahi manawa i ka makahiki i ka wā o ka hoʻohana ʻana o Jardins.

Hōʻike ʻia ka hoʻohana ʻana i ka lāʻau lapaʻau i ka wā kamaliʻi. ʻO nā pāpā i hoʻohana ʻia i nā maʻi āpau ma lalo o nā makahiki 18. ʻO kēia ma muli o ka nele o ka noiʻi no ka hopena a me ka palekana o ka lāʻau lapaʻau.

ʻAʻole ia e noʻonoʻo i ka hoʻohana ʻana i ka lāʻau lapaʻau ma ka mālama ʻana i nā mea maʻi ma luna o nā makahiki 75 makahiki. Hoʻopili pinepine kēia e pili me kahi kiʻekiʻe o ka hoʻolālāʻana o ka moku'āina o kahi dehydration.

ʻAʻole ʻoe e hoʻohana i ka pono hana i ka wā e mālama ai i nā poʻe maʻi e loaʻa ana i ka maʻi mellitus type 1 i nā hihia a i loaʻa i ka maʻi maʻi ketoacidosis maʻi.

Ke hoʻohana nei i ka nui o ka nui o ka lāʻau Jardins, ma kahi o 113 mg o ka lactose e komo ai i ke kino o ka mea maʻi.

ʻAʻole pono e hoʻohana kēia mea hana inā loaʻa ka lactase i ka nele o ka lactase, intolerance lactose a iʻole ka malabsorption glucose-galactose i loko o ke kino.

Nā hopena ʻaoʻao a me nā contraindications i ka wā e hoʻohana ai i ka lāʻau lapaʻau

ʻO ka hopena maʻamau e lawe i ka empagliflozin ʻo ka hoʻomaka ʻana o nā hōʻailona o ka hypoglycemia.

ʻO ka manawa pinepine, ka hopena hopena i ke ʻano o ka hypoglycemia e hōʻike pono ana i ka wā e hoʻohana ana i ka lāʻau lapaʻau i hui pū me nā derogatives sulfonylurea a i ʻole insulin.

I ka hoʻohui i ka hypoglycemia, hiki i nā mea maʻi e hoʻohana ana i ka empagliflozin hiki ke loaʻa i kahi nui o nā hopena ʻaoʻao.

ʻO nā hopena maʻamau loa ka hoʻohana ʻana i ka lāʻau lapaʻau nā mea penei:

1. ʻO ke ʻano o nā maʻi hōʻeha a me nā maʻi parasit e like me ka vulvovaginitis, balanitis, candidiasis vaginal, a me nā maʻi maʻi urinary.
2. Ma muli o nā hoʻololi o ke kaʻina metabolic i loko o ke kino, hiki ke loaʻa ka hypovolemia.
3. Hoʻonui nui i ka urination.
4. ʻO ka loaʻaʻana o nā hōʻailona o ka dehydration, ka mea i ʻike pinepine ʻia me ka hoʻohana ʻana i ka lāʻau lapaʻau i ka poʻeʻelemakule.

ʻO nā loiloi e pili ana i ka lāʻau lapaʻau, ka poʻe i hoʻohana iā ia, e hōʻike ana i nā hopena koʻikoʻi o ka hopena ma ke kino o ka mea maʻi. Ke kū ʻia mai nā hōʻailona mua o nā hopena ʻaoʻao, pono ʻoe e hoʻōki i ka lawe ʻana i ka lāʻau lapaʻau a ʻimi aku i ke kōkua i kāu kauka.

ʻO nā kumuhana nui i ka hoʻohana ʻana i ka lāʻau lapaʻau e like me kēia:

• maʻi diabetes type 1
• low rate glomerular filtration rate,
• maʻi maʻamau ketoacidosis,
• lactose intolerance,
• hapai a me lactation,
• kahi kūlana o ke kino e hoʻoweliweli ana i ka loaʻa o kahi dehydration.

Ma mua o ka lawe ʻana i ka lāʻau lapaʻau, pono ʻoe e kamaʻilio i kāu kauka a hana i ka hoʻokolokolo ʻana i ke kino no kekahi mau contraindications.

Nā hōʻike o ka lāʻau lapaʻau, ke kumukūʻai a me ka launa pū ʻana me nā lāʻau lapaʻau ʻē aʻe

I ka mākeke farmacological o Rūsia, ʻo Jardins wale nō ka lāʻau lapaʻau, i hana ʻia ma ke kumu o ka empagliflozin, ua kūʻai ʻia. Mai hiki iā mākou ke manaʻo e ʻaʻohe mea pili i kēia lāʻau lapaʻau ma ka mākeke Lūkini. ʻO nā mea'ē aʻe me nā hiʻohiʻona hypoglycemic ʻokoʻa ka hopena ma ke kino.

Kuhi ke kumukūʻai o ka lāʻau lapaʻau ma luna o ka wahi o ke kūʻai ʻana i ka lāʻau lapaʻau, e like me ka mea kūʻai mai o ka lāʻau. ʻO ka awelika uku o ka lāʻau Jardins ma Lūkia mai 850 a 1030 mau rubles.

Ke hoʻohana nei i ka lāʻau lapaʻau, pono e noʻonoʻo i ka hiki ke hoʻomaikaʻi i ka hopena diuretic o ka hoʻohana ʻana i kekahi diuretics thiazide, hiki iā ia ke hāʻawi i ka hoʻomohalaʻana o ka dehydration a me hypotension arterial.

ʻO ka mea hikiʻole ke hui pū me Jardins me nā lāʻau lapaʻau i hoʻolālā ʻia e hoʻonui i ke koko.

ʻO ka hoʻohana like ʻana o ka insulin synthetic, Jardins a me nā lāʻau lapaʻau e hoʻōla i ka hana o nā hormone kūlohelohe hiki ke hoʻowaluhi i ka ʻike o nā hōʻailona o ka hypoglycemia. Ke mālama nei i ka hōʻeha paʻakikī, mālama pono ʻia i ka hopena o ka lāʻau a me ka luna o nā lāʻau i lalo o ka mākaʻi a ke kauka e hele ana. A ʻo ke wikiō ma kēia ʻatikala e kamaʻilio e pili ana i ka mālama ʻana i nā maʻi maʻi diabetes.

Nā kumukūʻai no nā jardins i loko o nā lāʻau lapaʻau ma Moscow

Hōʻike nā kauka e pili ana i nā jardins

He kūpono loa ia e kū'ē ana i ka glycemia, kōkua i ka hāʻawi luhi.

ʻO ka hoʻonui pinepineʻana o nā pilikia urogenital.

He hopena maikaʻi kēia lāʻau lapaʻau i ka glycemia, akā koi aku i ka hoʻomaʻemaʻe maʻamau, ʻaʻole hiki ke kūpono i nā maʻi āpau. Ma waho o ka nānā ʻana i nā lula o ka papaʻai o ka papaʻai, hiki ke loaʻa i nā kuhikuhi kuhikuhi o ka hana kālai a me ka hopena nui o ka glycemia. ʻO ka hōʻemi ʻana i ka calorie intake ma muli o ka laweʻana o ka glucose i ka urine he hopena maikaʻi hou nō naʻe, akā naʻe, i kaupalena ʻia i ka manawa.

ʻO ia kahi lāʻau lapaʻau kūpono loa no nā poʻe maʻi me ka maʻi mellitus a me ka male ʻana o ka puʻuwai naʻau.

ʻO ka mole i loko o kēia mau mea maʻi he meli gula, ke hoʻonui nui nei i nā pilikia o nā maʻi ʻōpiopio. Pono nā mea maʻi e nānā pololei. Makemake wau e hoʻomanaʻo i ka lula FDA e pili ana i ka kiʻekiʻe o ka gang perineal perineal ma muli o ka ʻoi o ka nui o ke ʻano o ka maʻi kāne.

ʻO kēia lāʻau lapaʻau kahi ʻano hoʻohuli i ka cardiology. ʻO ka maʻi mellitus ke lilo lohi nei i lilo he lālā o ka cardiology, a ʻo ia ke ʻano mua o ka lāʻau lapaʻau maʻi ʻoiaʻiʻo maoli me nā mea pōmaikaʻi e pili ana i kona hopena ma ka ʻōnaehana cardiovascular.

ʻO kahi hypoglycemic maikaʻi loa no ka maʻi type 1 ka maʻi. Hele maikaʻi me nā hua lāʻau hypoglycemic a me ka insulin. Loaʻa kekahi hopena diuretic kūlohelohe.

ʻO ke kumukūʻai ma luna o ke kiʻekiʻe.

He hana nui. Hoʻomaopopo ka poʻe maʻi i ka hōʻoluʻolu o ka hoʻohana ʻana - 1 manawa i kēlā me kēia lā, kahi hoʻomaikaʻi koʻikoʻi i ka hoʻokō ʻana i ka mea maʻi.

ʻO ka lāʻau "Jardins" ʻoi aku ka maikaʻi ma ka manawa no ka mālamaʻana i ka maʻi maʻi. Ua hoʻopaʻa ʻia kēia lāʻau lapaʻau ma ka Russian Federation. He nui nā mea maʻi e kapa iā ia "nā pilahi insulin." Hōʻike wikiwiki ʻia ka hopena. I kēia lā, ʻo kēia lāʻau lapaʻau ke koho aku i ka insulin.

Nā Hōʻike Manaʻo Jardins manawanui

Ua hoʻokumu ʻia ka maʻi mai ka 2012. ʻAʻole i emi ka Sugar me nā lāʻau lapaʻau, no laila, ua kau wikiwiki ka mea i kau i ka insulin no nā makahiki 3. I ka manawa mua, mālama ia i 16-14 mau ʻāpana, a laila 18-16, a me ka 4 mau mahina i hala. 22-18 hui Akā ʻaʻole e loli ke kauka i nā mea lapaʻau, hoʻonui wale ʻia i ka lāʻau. A pēlā i hiki ai, hana nā Jardins me ke kōkua kanaka kōkua, i hoʻopuka ʻia no kahi hōʻike. Ma hope o ʻekolu mau lā, hoʻoili gula - 10 mau ʻāpana, a me 8 mau ʻāpana. Uaʻike wau i ka ikaika a makemake wau e ola! Akā no ka malama hoʻokahi, ʻaʻole lākou e kākau no ka manuahi, ʻaʻohe ala ʻē aʻe e kūʻai iā ʻoe iho. Akā ke noi ikaika nei au, no ka mea ʻaʻole i holomua ka hoʻomaʻamaʻa ʻana, e kōkua maoli nō ia.

Lapaʻau

ʻO ka lāʻau lapaʻau hypoglycemic oral. He hoʻohuli ʻo Empagliflozin i kahi hoʻoikaika, ikaika loa, koho a hoʻoneʻe i ke kō o ka sodium type 2 sodium-dependence me ke kūpaʻa e koi ai i ka 50% o ka hana enzyme (IC₅₀), e like me 1,3 nmol. ʻO ka koho ʻana o ka empagliflozin he 5,000 mau manawa i ʻoi aku ma mua o ka hoʻohana ʻana o ka mea hoʻonaninani glucose mālaʻa o ka sodium e kuleana no ka hoʻopio ʻana o ka glucose i loko o ka ʻawaʻawa.

Eia kekahi, ua loaʻa ka empagliflozin i kahi koho kiʻekiʻe no nā transporters glucose hou ke kuleana no ka home home home glucose.

ʻO ka sodium-hilinaʻi type 2 glucose transporter ka mea nui e lawe ai i ka protein lawe nui e pili ana i ka reabsorption o ka glucose mai ka glomeruli renal i loko o ke kahe wai.

Hoʻomaikaʻi ʻo Empagliflozin i ka mana glycemic i loko o nā mea maʻi me ka maʻi diabetes type 2 ma o ka hoʻēmi ʻana i ka reabsorption luaʻa. ʻO ka nui o ka glucose i hilo ʻia e nā keiki e hoʻohana i kēia hana hiki ke pili i ke kūpaʻa o ka glucose i ke koko a me GFR. ʻO ka wehe ʻana o ka mea lawe sodium e hilinaʻi nei i ka hoʻohālikelike type 2 i nā mea maʻi me ka diabetes type 2 a me ka hyperglycemia alakaʻi i ka hoʻohemo ʻana o ka nui o ka glucose e nā pōʻai.

Ma nā hoʻokolohua haukapila, ua ʻike ʻia aia i loko o nā mea maʻi me ka diabetes type 2, ua hoʻonui ʻia ka hoʻōla o ka glucose ma nā huaʻai ma hope koke o ka hopena mua o ka empagliflozin, ua hoʻomau ʻia kēia hopena no nā hola 24. ka hoʻohana ʻana o ka empagliflozin i kahi manawa o 25 mg 1 manawa / lā, ma kēlā me kēia, e pili ana iā 78 g / lā. I ka poʻe maʻi me ka diabetes mellitus type 2, kahi piʻi o ka excretion o glucose i nā huaʻai i alakaʻi koke i ka kao o ka glucose i loko o ke koko koko.

Hoʻopau i ka Empagliflozin i ke kukuna o ka glucose i ka pulu koko a i ke ʻano no ka wikiwiki a ma hope o ka ʻai ʻana.

ʻO ka hana o ka hana o ka empagliflozin ʻaʻole i hilinaʻi i ka kūlana hana o ka pancreatic β-cell a me ka metabolism insulin. Ua hōʻike ʻia ka hopena maikaʻi o ka empagliflozin i ka poʻe hoʻohālikelike i ka hana o nā hana β-cell, me ka HOMA-β index (kumu hoʻohālike i ka homeostasis) a me ka hoʻohālikelike o ka proinsulin i ka insulin. Hoʻopili ia, ʻo ke kāpae ʻana o ka glucose i nā huaʻai e hōʻeha i ka hina o ke kaloli, e hoʻopili ʻia me ka hoʻemi ʻana o ka nui o ke kiko adipose a me ka hoʻolilo ʻana i ke kaupaona kino.

Loaʻa ka Glucosuria i ka wā o ka hoʻohana ʻana i ka empagliflozin i hoʻopili ʻia me ka piʻi iki o ka diuresis, hiki iā ia ke hāʻawi i kahi emi o ke kahe o ke koko.

I nā haʻawina ma kahi i hoʻohana ai ka empagliflozin i mea monotherapy, hui pū me ka metformin, hui hui pū me ka metformin i nā poʻe maʻi me ke ʻano maʻi diabetes ʻano hou 2 mellitus, hui hui pū me ka metformin a me nā konopulepo sulfonylurea, hui hui pū me ka pioglitazone +/- metformin, hui hui pū me ka linagliptin i loko o nā mea maʻi me ka maʻi diabetes type 2 hou ke ʻano hou, hui pū me ka linagliptin, i hoʻohui ʻia i ka metformin therapy, hui pū ʻO ka FDI me ka metformin versus glimepiride (data mai kahi noiʻi 2 mau makahiki), hui pū me ka insulin (nui i nā inikini insulin) +/- metformin, hui hoʻohui me ka basal insulin, hui pū me ka peptidyl peptidase-4 inhibitor (DPP-4), metformin +/- ua hōʻike ʻia kekahi lāʻau lapaʻau hypoglycemic waha loa ka loaʻa ʻana o ka nui o ka hōʻemi i ka hemoglobin glycosylated (Hb_A1c), kahi hōʻemi o ka hoʻoliʻiliʻi ʻana o ka glucose glucose, a me kahi hoʻohaʻahaʻa i ke koko a me ke kaumaha o ke kino.

Lapaʻau lāʻau

Ua hōʻike nui ʻia nā pharmacokinetics o empagliflozin i nā poʻe hana olakino olakino a me nā mea maʻi me nā maʻi maʻi type 2.

Ma hope o ka nānā ʻana, ua hoʻokomo koke ʻia ka empagliflozin, C_max empagliflozin i loko o ke koko koko ua hiki aku ma hope o nā hola 1.5. A laila, ʻo ka huli ʻana o ka empagliflozin i loko o ka plasma e hoʻoemi ana i ka biphasic. ʻO ka awelika AUC i ka wā o ka hoʻokūkū plasma paʻa i ka 4740 nmol × h / l, a me ke kumukūʻai C_max - 687 nmol / L. ʻAʻohe ʻai nui i ka hopena ma ka pharmacokinetics o empagliflozin.

ʻO nā pharmacokinetics o empagliflozin i nā mea hana olakino olakino a me nā poʻe maʻi me ka maʻi diabetes mellitus type 2 like loa.

V_{e d} i ka manawa o ka hoʻomau mau ʻana i loko o ke kaila koko e hana ma kahi o 73.8 l. Ma hope o ka lawelawe waha ʻana e nā mea ikaika olakino o ka mea i loaʻa ka inoa ʻo emagliflozin 14 C, ʻo ka palena o ka protein protein he 86%. Ke hoʻohana nei i ka empagliflozin 1 manawa / lā C_{ai ʻo ss} i ka plasma i hōʻea ma hope o ka kaha o ka ʻelima.

ʻO ke ala nui o ka metabolism empagliflozin i loko o ke kanaka he glucuronidation me ka komo ʻana o ka uridine-5'-diphospho-glucuronosyltransferases UGT2B7, UGT1A3, UGT1A8 a me UGT1A9. ʻO nā metabolites ka mea i ʻike nui ʻia e pili ana i ka empagliflozin ʻekolu mau mea huakaʻi glucuronic (2-O, 3-O a me 6-O glucuronide). ʻO ka hopena systemic o kēlā me kēia metabolite ka liʻiliʻi (ma lalo o 10% o ka hopena piha o ka empagliflozin).

T_1/2 ma kahi o nā hola 12.4 Ma hope o ka nānā ʻana o ka inoa ʻo empagliflozin 14 C i nā mea olakino olakino, ma kahi o 96% o ka nui i kāʻai ʻia (ma loko o nā ʻōpū - 41%, nā pēpē - 54%). Ma loko o nā ʻōpū, ʻaʻole i hoʻololi ʻia ka hapa nui o ka lāʻau hōʻailona. Hoʻokahi wale nō hapa o ka lāʻau hōʻailona i hoʻopili ʻia ʻole e nā keiki.

ʻO ka Pharmacokinetics i nā hui hoʻomanawanui kūikawā

I nā maʻi me ka hōʻemi, hoʻohaʻahaʻa, a me ka hikiʻole ke nānā aku (30 2) a i nā mea maʻi me ka hopena o ka hanana hope loa, ʻoi aku ka nui o ka AUC o ka hoʻohiki ʻana ma lalo o ka 18%, 20%, 66%, a me 48%, pākahi me nā mea maʻi me ka hana maʻamau nā pōpō. I nā mea maʻi me ka hiki ʻole o ka maikaʻi ʻole o ka pale a me nā mea maʻi me nā hopena hope loa hope C_max ʻo ka empagliflozin i ka plasma ua like like me nā waiwai kūpono i nā mea maʻi me ka hana maʻamau. I ka poʻe maʻi me ka hōʻeha a me ka maikaʻi ʻole o ka pale_max empagliflozin i loko o plasma i kahi 20% kiʻekiʻe ma mua o nā mea maʻi me ka hana maʻamau maʻamau. Ua hōʻike nā hōʻike noiʻi pharmacokinetic i hōʻike i ke koena o ka hoʻomaʻemaʻe ʻana o nā empagliflozin i hoʻohaʻahaʻa me ka hoʻohaʻahaʻa i ka GFR, i alakaʻi ai i ka hopena o ka lāʻau lapaʻau.

I nā maʻi me ka maʻi hōʻemi, maʻalahi, a me nā maʻi hepatic koʻikoʻi (e like me ka helu ʻana o nā keiki-Pugh), ʻo ka AUC o ka empagliflozin i hoʻonui ʻia ma aneane 23%, 47%, a me 75%, kēlā me kēia,_max like me 4%, 23% a me 48%, kēlā me kēia (hoʻohālikelike ʻia me nā mea maʻi me ka hana maʻamau puʻuwai).

ʻAʻole i loaʻa kahi hopena koʻikoʻi o ka BMI, ka wahine, ka lāhui, a me ka makahiki i nā pharmacokinetics o empagliflozin.

ʻAʻole i hana ʻia nā noi ʻana o nā pharmacokinetics o empagliflozin i loko o nā keiki.

E hoʻokuʻu i ke ʻano

ʻO nā papa, nā kala i ulana ʻia, he melemele i ke kala, hoʻopuni, biconvex, me nā kihi beveled, i kahakaha ʻia me ka hōʻailona o ka hui ma kekahi ʻaoʻao a me "S10" ma kēlā me kēia.

Nā mea hoʻihoʻi:: ka lōmole lactose - 162.5 mg, cellulose microcrystalline - 62.5 mg, hyprolose (hydroxypropyl cellulose) - 7.5 mg, sodium croscarmellose - 5 mg, silikone koloila kaila - 1.25 mg, magnesium stearate - 1.25 mg.

Ka hana hui: Opadry meli (02B38190) - 7 mg (hypromellose 2910 - 3.5 mg, titanium dioxide - 1.733 mg, talc - 1,4 mg, macrogol 400 - 0.35 mg, iron oxide yellow - 0.018 mg).

10 kamepiula - nā kāmele (1) - nā ʻeke pepa.
10 kamepiula - blisters (3) - nā ʻeke pepa.

Lawe ʻia ka lāʻau lapaʻau ma ke ʻano, i kēlā me kēia manawa o ka lā, me ke ʻano o ka komo ʻana o ka meaʻai.

ʻO ka papa hoʻomaka ʻia he 10 mg 1 mau lā / lā. Inā hāʻawi ʻole ʻia ka nui o kēlā me kēia lā iā 10 mg i kahi mau glycemic kūpono, hiki ke hoʻonui ʻia i kēia momona i 25 mg 1 manawa / lā.

ʻO ka dose kiʻekiʻe loa i kēlā me kēia lā he 25 mg.

Ke hoʻoluhi nei i kahi maʻa, pono e lawe ka mea maʻi i ka lāʻau ma ka manawa e hoʻomanaʻo ai i kēia. Mai lawe i kahi pāpālua pālua i ka lā hoʻokahi.

No ka poʻe maʻi me ka wehe ʻole ʻana o ka GFR mai 45 a 90 ml / min / 1.73 m 2, ʻaʻole koi ʻia ka hoʻoponopono ʻana. I ka poʻe maʻi me ka pilikia kīleʻa me ka GFR 2, ʻaʻole i ʻōlelo ʻia ka hoʻohana o ka lāʻau ma muli o ka hikiʻole.

ʻO nā mea maʻi me ka maʻi luhi functioning lawelawe ʻole ʻaʻole pono.

Hoʻohui

Hiki i ka Empagliflozin ke hoʻonui i ka hopena diuretic o thiazide a me ka "loop" diuretics, a ma ia manawa, e hoʻonui ai i ka hōʻeha o ka dehydration a me hypotension arterial.

ʻO ka insulin a me nā lāʻau lapaʻau e hoʻoikaika i kāna mea huna, e like me ka sulfonylureas, e hoʻonui i ka ʻeha o ka hypoglycemia. No laila, me ka hoʻohana pū ʻana o empagliflozin me ka insulin a me nā lāʻau lapaʻau e hoʻoikaika ai i kona ʻimi, pono paha e hōʻemi i kā lākou dosis, i mea e pale ai i ka maʻi o ka hypoglycemia.

I ka hōʻike vitro hoʻonaninau lāʻau. ʻAʻole i hoʻopaʻa ai ʻo Empagliflozin i ka hana, ʻaʻole hoʻohālikelike, a i ʻole hoʻohiolo iā CYP450 isoenzymes. ʻO ke ala nui o ka metabolism empagliflozin i loko o nā kānaka he glucuronidation me ke komo ʻana o ka uridine-5'-diphospho-glucuronosyltransferases UGT2B7, UGT1A3, UGT1A8 a me UGT1A9. ʻAʻole ʻo Empagliflozin e kāohi iā UGT1A1. ʻO nā hōʻiliʻili o ka lālani o ka empagliflozin a me nā lālani i hoʻohālikelike i ka CYP450 a me UGT1A1 isoenzymes i manaʻo ʻia i like ʻole.

ʻO Empagliflozin kahi papa hana i ka P-glycoprotein a me ka pale ʻana i ka pale umauma e hoʻoholo ana i ka protein (BCRP), akā ʻaʻole ia i pale i kēia mau protein ma ke ʻano therapeutic. Ma muli o ka ʻikepili mai nā haʻawina vitro, ʻike ʻia ka hiki ʻole o ka empagliflozin ke hoʻopili me ka lāʻau lapaʻau e substrates no ka P-glycoprotein i like ʻole. ʻO Empagliflozin kahi papa lepo no nā mea lawe anionic organik: OAT3, OATP1B1 a me OATP1B3, akā ʻaʻole ia kahi papa kuhikuhi no ka mea lawe anionic meaola 1 (OAT1) a me nā mea lawe cationic carriers 2 (OST2). Eia naʻe, ʻo ka loaʻa ʻana o ka lāʻau lapaʻau ka empagliflozin me nā lāʻau lapaʻau nā substrates no nā mea lawe palaka e pili ana i luna e manaʻo ʻia he mea makemake ʻole.

Ma ka vivo lāʻau e hoʻoponopono nei i ka loiloi. Me ka hoʻohana pū ʻana o empagliflozin me nā lāʻau lapaʻau maʻamau, ʻaʻohe i ʻike ʻia ka launa pūlapa. Hōʻike nā hopena o nā noiʻi pharmacokinetic ʻaʻole pono e hoʻololi i kēiaʻano o ka lāʻau lapaʻau Jardins ® aʻo ia ka mea me nā lāʻau lapaʻau maʻamau.

ʻAʻole loli i ka pharmacokinetics o empagliflozin i nā mea hana olakino maikaʻi i ka wā i hoʻohana pū ʻia me metformin, glimepiride, pioglitazone, sitagliptin, linagliptin, warfarin, verapamil, ramipril, simvastatin, torasemide a me hydrochlorothiazide. ʻO ka hui pū ʻana o ka empagliflozin me gemfibrozil, rifampicin a me ka probenecid i hōʻike i ka hoʻonui ʻia ʻana o ka AUC o empagliflozin e 59%, 35% a me 53%, akā, ʻaʻole i manaʻo ʻia kēia mau loli.

ʻAʻole ka hopena o Empagliflozin i ka hopena nui ma ka pharmacokinetics o ka metformin, glimepiride, pioglitazone, sitagliptin, linagliptin, warfarin, digoxin, ramipril, simvastatin, hydrochlorothiazide, torasemide a me nā mea hoʻohiwahiwa i loko o nā limahana olakino.

Nā hopena hopena

ʻO ka nui o ka ulu ʻana i nā hanana ʻino i ka poʻe maʻi e loaʻa ana i ka empagliflozin a i ʻole placebo e like nō me nā haʻawina ma klinik. ʻO ka hopena maʻamau loa, ʻo ia ka hypoglycemia, i ʻike ʻia me ka hoʻohana ʻana i ka empagliflozin i hui pū ʻia me sulfonylurea a i ʻole derivatives i insulin.

ʻO nā hōʻike ʻinoʻino i ʻike ʻia i nā maʻi e loaʻa ana i ka empagliflozin i nā haʻawina hoʻokele i ka pletebo i hōʻike ʻia ma lalo nei e like me ka helu ʻana o nā kino a me nā ʻoihana a me nā huaʻōlelo i makemake ʻia ʻo MedDRA e hōʻike nei i ko lākou holoʻokoʻa ʻana. ʻO ka koho pinepine ʻia ka ʻano e like me: pinepine pinepine (≥1 / 10), pinepine pinepine mai (mai ≥1 / 100 a me 2,

Me ka mālama pono: nā mea maʻi me ka hopena o ka hoʻomohala ʻana i ka hypovolemia (ka hoʻohana ʻana i nā lāʻau antihypertensive me ka mōʻaukala o ka hypotension arterial), me nā maʻi gastrointestinal e alakaʻi ana i ka poho o ka wai, nā maʻi o ka ʻōnaehana genitourinary, i hui pū me ka sulfonylureas a i nā derivatives i insulin, kahi meaʻai liʻiliʻi-carb, ketoacidosis diabetes. mōʻaukala, nā hana huna haʻahaʻa o nā peka beta pancreatic, nā mea maʻi ma luna o nā makahiki 75 makahiki.

ʻŌpū a me ka lactation

Hoʻohana ʻia ka hoʻohana ʻana o ka empagliflozin i ka wā hapai ma muli o ka lawa ʻole o ka ʻikepili i ka pono a me ka palekana.

Hoʻohana ʻia ka hoʻohana ʻana o ka empagliflozin i ka wā o ka hoʻoulu ʻana. ʻO nā ʻikepili i loaʻa i nā noi preclinical i nā holoholona e hōʻike ana i ka noho kaawale o ka empagliflozin me ka waiū umauma. ʻAʻole i pale ʻia ka hopena o ka hoʻolaha ʻana i nā pēpē a me nā keiki hānai hānai. Inā pono e hoʻohana i ka empagliflozin i ka wā lactation, pono ke hoʻokaʻawale ka pale umauma.

Hoʻohana no ka hana renal impaired

ʻO ka hana o ka lāʻau Jardins ® pili i ka hana o nā kuhi. No laila, paipai ʻia e mālama i nā hana o ka keiki ma mua o ka manawa i kuhikuhi ʻia a mālama ʻia i ka wā o ka mālama ʻana (ma kahi o ka manawa 1 ka manawa i kēlā me kēia makahiki), a ma mua hoʻi o ke koho ʻia ʻana o ka hui concomitant, hiki i ka mea pili i ka hana o ke keiki.

No ka poʻe maʻi me ka wehe ʻole ʻana o ka GFR mai 45 a 90 ml / min / 1.73 m 2, ʻaʻole koi ʻia ka hoʻoponopono ʻana. I ka poʻe maʻi me ka pilikia kīleʻa me ka GFR 2, ʻaʻole i ʻōlelo ʻia ka hoʻohana o ka lāʻau ma muli o ka hikiʻole.

Hoʻohana i nā mea maʻi maʻi

ʻO nā maʻi o ka makahiki 75 a keu a ʻoi aku ka nui o ka ulu ʻana o ka puʻuwai. I kēlā mau mea maʻi i mālama ʻia me ka empagliflozin, ʻoi aku ka maikaʻi loa o nā hopena i loaʻa e ka hypovolemia (hoʻohālikelike ʻia me nā mea maʻi e loaʻa ana i ka placebo).

Loaʻa ka ʻike me ka empagliflozin i nā mea maʻi ma luna o ka 85 makahiki o kona mau makahiki, no laila, ʻaʻole pono e kuhikuhi i ka lāʻau lapaʻau Jardins ® i ka poʻe maʻi o kēia ʻano makahiki.